Get the Daily Brief
Latest Biotech News
IL‑12‑releasing nanoparticles enable durable ovarian tumor clearance with checkpoint inhibitors
MIT researchers reported polymer‑coated nanoparticles that deliver IL‑12 directly to ovarian tumors, markedly enhancing responses to immune checkpoint inhibitors in mouse models. Preclinical data...
Ultra‑broad hybrid capture NGS detects circulating pathogen DNA in plasma
A team published a hybrid capture–based targeted NGS approach that amplifies detection of circulating microbial cell‑free DNA in blood plasma, enabling broader pathogen discovery and potential...
FDA signals deregulation push — agency guidance and bespoke gene‑therapy pathway guidance emerge
FDA Commissioner remarks signaled an intent to pursue further 'deregulatory' initiatives following recent relaxations in biosimilar trial requirements, indicating a regulatory tone favoring...
Pfizer sues to block Metsera sale—Novo bid triggers courtroom fight
Pfizer filed suit in the Delaware Court of Chancery seeking to enforce its $4.9 billion merger agreement with obesity biotech Metsera and to block an unsolicited rival offer from Novo Nordisk....
FDA places Intellia CRISPR trials on hold: liver safety probe
The FDA imposed a clinical hold on two Phase 3 studies of Intellia’s CRISPR gene‑editing therapy nexiguran ziclumeran (nex‑z) following reports of liver complications. The hold covers trials in...
Moderna retreats: cuts, canceled contracts and a pivot after Covid boom
Moderna reported shrinking Covid vaccine revenues, workforce reductions and tightened spending as federal contracts were canceled and product expectations cooled. The company lost a $766 million...
Gene therapy ‘cure’ for ADA‑SCID posts 95% success—UCL, UCLA follow‑up
A joint UCL‑UCLA research initiative reported multi‑year follow‑up showing their gene therapy for ADA‑SCID restored immune function in roughly 95% of treated children with no serious long‑term...
Scalable human kidney organoids integrated with porcine kidneys—transplant step
Researchers published a Nature Biomedical Engineering study demonstrating a scalable method to produce thousands of human kidney organoids and to integrate them into perfused porcine kidneys ex...
IL‑12 nanoparticles plus checkpoint inhibitors wipe out ovarian metastases in mice
MIT and collaborators reported in Nature Materials that polymer‑coated nanoparticles engineered to deliver IL‑12 directly to ovarian tumor sites produced durable antitumor immunity when combined...
Patent cliff looms—Biopharma M&A surges as companies chase new revenues
Industry analysis found approximately $230 billion in annual sales tied to top blockbusters facing patent expirations through 2029, triggering accelerated M&A and portfolio reshaping across big...
Engineered Cas9 and Baby KJ pathway: lab fixes meet regulatory playbook
A University of California Berkeley team reported a protein engineering strategy that increases Cas9 nuclear import by inserting additional nuclear localization signals into surface loops,...
Myeloid and tumor genomic mechanisms map immunotherapy resistance
Dana‑Farber investigators identified interferon‑gamma signaling within tumor‑associated myeloid cells as a driver of resistance to immune checkpoint inhibitors in advanced renal cell carcinoma....
AI sharpens discovery—binding affinity models and scaled virtual cells
MIT and Recursion’s Boltz‑2 model demonstrated rapid, accurate binding‑affinity predictions, reporting affinity calculations in seconds and matching top performance in recent CASP benchmarking....
Pfizer sues to enforce Metsera buyout — court fight ignites
Pfizer sued Metsera and Novo Nordisk in Delaware’s Court of Chancery to block Metsera from terminating a September buyout agreement, alleging Novo’s rival bid breaches the merger pact and...
Moderna’s post‑Covid pivot falters — layoffs, contract losses and valuation collapse
A detailed report chronicles Moderna’s rapid reversal from pandemic-era hero to a company under heavy financial and strategic pressure. Executives have cut costs and reorganized after...
FDA halts Intellia’s CRISPR trials after liver safety signals
The FDA imposed a clinical hold on Intellia’s Phase 3 trials of nexiguran ziclumeran (nex‑z), a CRISPR‑based in vivo gene‑editing therapy for transthyretin amyloidosis, after investigators...
Gene therapy milestone: ADA‑SCID ‘cure’ shows durable success
A joint UCL–UCLA research program reported long‑term, disease‑modifying results for an ADA‑SCID gene therapy, with a multi‑year follow‑up showing roughly 95% success and no serious safety signals....
Human kidney organoids scaled and grafted into porcine kidneys
Researchers published a pair of advances: a reproducible, scalable protocol to produce thousands of human kidney organoids and the first successful integration of those organoids into perfused...
Thermo Fisher moves on Clario — $8.88B buy to tighten clinical data stack
Thermo Fisher Scientific agreed to acquire Clario Holdings for $8.88 billion in cash, aiming to integrate Clario’s endpoint data and patient‑centric clinical trial technology into Thermo’s...
Cas9 delivery and Baby KJ dossier reshape bespoke gene‑therapy pathway
A UC Berkeley team reported a protein‑engineering strategy that inserts additional nuclear localization signals into internal Cas9 loops to substantially increase nuclear import and gene‑editing...